1-4 of 4
Patrick Miossec
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

Julio Rosenstock, MD, Denis Raccah, MD, László Korányi, DSC, Laura Maffei, MD, Gabor Boka, MD, Patrick Miossec, MD, John E. Gerich, MD
Journal: Diabetes Care
Diabetes Care 2013;36(10):2945–2951
https://doi.org/10.2337/dc12-2709
Published: 14 September 2013
View article titled, Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: <subtitle>A 24-week, randomized, open-label, active-controlled study (GetGoal-X)</subtitle>
Open the PDF for Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: <subtitle>A 24-week, randomized, open-label, active-controlled study (GetGoal-X)</subtitle> in another window
Includes: Supplementary data
Journal Articles

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)

Matthew C. Riddle, MD, Ronnie Aronson, MD, FRCPC, FACE, Philip Home, DPHIL, DM, FRCP, Michel Marre, MD, PHD, Elisabeth Niemoeller, MD, Patrick Miossec, MD, Lin Ping, MD, Jenny Ye, Julio Rosenstock, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2489–2496
https://doi.org/10.2337/dc12-2454
Published: 13 August 2013
View article titled, Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: <subtitle>A 24-week, randomized, placebo-controlled comparison (GetGoal-L)</subtitle>
Open the PDF for Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: <subtitle>A 24-week, randomized, placebo-controlled comparison (GetGoal-L)</subtitle> in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

Bo Ahrén, MD, Aniceto Leguizamo Dimas, MD, Patrick Miossec, MD, Stéphane Saubadu, MD, Ronnie Aronson, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2543–2550
https://doi.org/10.2337/dc12-2006
Published: 13 August 2013
View article titled, Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
Open the PDF for Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M) in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Vivian A. Fonseca, MD, Ricardo Alvarado-Ruiz, MD, Denis Raccah, MD, Gabor Boka, MD, Patrick Miossec, MD, John E. Gerich, MD, on behalf of the EFC6018 GetGoal-Mono Study Investigators
Journal: Diabetes Care
Diabetes Care 2012;35(6):1225–1231
https://doi.org/10.2337/dc11-1935
Published: 11 May 2012
View article titled, Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: <subtitle>A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)</subtitle>
Open the PDF for Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: <subtitle>A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)</subtitle> in another window
Includes: Supplementary data